Seven-Day Continuous Abstinence Rate from Smoking at 1, 2, or 3 Years after the Use of Varenicline
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jin Se | - |
dc.contributor.author | Jang, Ju Young | - |
dc.contributor.author | Park, Eun Hye | - |
dc.contributor.author | Lee, Joo Young | - |
dc.contributor.author | Gu, Kang Mo | - |
dc.contributor.author | Jung, Jae Woo | - |
dc.contributor.author | Choi, Jae Chol | - |
dc.contributor.author | Shin, Jong Wook | - |
dc.contributor.author | Park, In Won | - |
dc.contributor.author | Choi, Byoung Whui | - |
dc.contributor.author | Kim, Jae Yeol | - |
dc.date.available | 2019-03-08T17:39:50Z | - |
dc.date.issued | 2015-04 | - |
dc.identifier.issn | 1738-3536 | - |
dc.identifier.issn | 2005-6184 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/9667 | - |
dc.description.abstract | Background: Varenicline, a selective partial agonist/ antagonist of the alpha 4 beta 2 nicotinic receptor, has proven effectiveness for smoking cessation by several randomized, controlled trials. Because few studies have evaluated the long-term efficacy of varenicline, we tried to evaluate the smoking status of varenicline users up to 3 years after the initial prescription of the drug. Methods: We interviewed varenicline users who were prescribed the drug from June 2007 to May 2010 by telephone, from June 2010 to May 2011. Results: One- hundred and thirty- three of 250 varenicline users (53.2%) were available for the survey. Seven-day continuous abstinence from smoking was adhered to by 17 of 39 respondents (43.6%) at 1 year, and 11 of 36 (30.6%) and 19 of 58 (32.8%) at 2 and 3 years since the first use of varenicline, respectively. Compared to current smokers, successful quitters were older (55.0 years vs. 49.9 years, p=0.01), had better compliance to the 12-week course (27.7 vs. 9.3%, p=0.01), and had taken varenicline longer (10.1 vs. 5.9 weeks, p=0.01). Fifty- four of 71 current smokers (76.1%) were willing to stop smoking in the near future. The preferred ways to cease smoking were will-power (48.1%), varenicline (25.9%), nicotine replacement therapy (11.1%), and others (14.9%). Conclusion: Smokers should be encouraged to stick to the proven way for recommended period of time for successful cessation of smoking. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | TAEHAN KYORHAEK HYOPHOE-KOREAN ACAD TUBERCULOSIS & RESPIRATORY DISEASES | - |
dc.title | Seven-Day Continuous Abstinence Rate from Smoking at 1, 2, or 3 Years after the Use of Varenicline | - |
dc.type | Article | - |
dc.identifier.doi | 10.4046/trd.2015.78.2.92 | - |
dc.identifier.bibliographicCitation | TUBERCULOSIS AND RESPIRATORY DISEASES, v.78, no.2, pp 92 - 98 | - |
dc.identifier.kciid | ART001978621 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000420537000007 | - |
dc.identifier.scopusid | 2-s2.0-84929399370 | - |
dc.citation.endPage | 98 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 92 | - |
dc.citation.title | TUBERCULOSIS AND RESPIRATORY DISEASES | - |
dc.citation.volume | 78 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Compliance | - |
dc.subject.keywordAuthor | Smoking | - |
dc.subject.keywordAuthor | Varenicline | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.